Table 3.
Comparison of 5-year overall survival rates in patients with and without TDs in pN stage.
| Variables | TD– | TD+ | P value* | ||
|---|---|---|---|---|---|
| No. (%) | 5-Y OS (%) | No. (%) | 5-Y OS (%) | ||
| Training cohort | |||||
| pN1a | 1,948 (30.2) | 81.7 | 131 (2.0) | 69.2 | <0.001 |
| pN1b | 1,853 (28.8) | 76.4 | 177 (2.7) | 63.1 | <0.001 |
| pN1c | 0 | – | 273 (4.2) | 75.5 | – |
| pN2a | 1,041 (16.2) | 69.2 | 150 (2.3) | 57.2 | 0.001 |
| pN2b | 738 (11.5) | 53.0 | 129 (2.0) | 40.1 | 0.017 |
| Validation cohort | |||||
| pN1a | 850 (30.8) | 79.9 | 59 (2.1) | 53.1 | <0.001 |
| pN1b | 760 (27.6) | 72.8 | 66 (2.4) | 65.6 | 0.043 |
| pN1c | 0 | – | 140 (5.1) | 70.2 | – |
| pN2a | 466 (16.9) | 67.0 | 38 (1.4) | 46.9 | 0.015 |
| pN2b | 321 (11.6) | 60.8 | 58 (2.1) | 39.7 | 0.008 |
No., number; OS, overall survival; pN, pathological N; TD, tumor deposit; Y, year.
*P value based on log-rank test, TD+ vs. TD–.